Portal venous hypertension is elevated blood pressure within the portal venous system — the network of veins that carries nutrient-rich blood from the intestines, spleen, stomach, and pancreas to the liver. When flow through the liver becomes obstructed, pressure builds upstream and forces blood through collateral pathways that are not designed to handle high pressures. These collaterals produce the life-threatening complications that define the clinical syndrome.
Portal hypertension is almost always a complication of another underlying liver or vascular condition. Cirrhosis — from any cause including fatty liver disease, alcohol-related liver disease, or viral hepatitis — is responsible for over 90% of cases. The complications of portal hypertension are the same decompensation events that mark the transition from compensated to life-threatening cirrhosis. Splenomegaly is one of the most reliable imaging markers of portal hypertension and reflects the chronic backup of blood into the splenic vein. On MRI, the portal venous anatomy, collateral vessels, and liver findings are evaluated simultaneously — providing a complete picture of the severity and consequences of portal hypertension in a single examination.
Causes
Intrahepatic causes (by far the most common).
Cirrhosis is responsible for the overwhelming majority of portal hypertension cases. Progressive hepatic fibrosis obliterates the sinusoidal spaces — the tiny channels through which portal blood normally flows at low pressure — and the resulting increase in intrahepatic vascular resistance elevates portal venous pressure. The normal portal vein pressure gradient (hepatic venous pressure gradient, HVPG) is 1–5 mmHg; clinical complications of portal hypertension — varices, ascites — develop when HVPG exceeds 10–12 mmHg. Any cause of cirrhosis produces this intrahepatic obstruction pattern, including fatty liver disease (MASLD/MASH), alcohol-associated liver disease, chronic hepatitis B and C, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.
Pre-hepatic and post-hepatic causes.
Pre-hepatic portal hypertension — obstruction before blood reaches the liver — is most commonly caused by portal vein thrombosis, which can occur in the setting of hypercoagulable states (factor V Leiden, antiphospholipid syndrome, myeloproliferative disorders), intra-abdominal infection or inflammation, or following abdominal surgery. Because the liver parenchyma is normal in pre-hepatic disease, liver function is typically well preserved even with significant portal hypertension. Post-hepatic portal hypertension — obstruction of venous drainage from the liver — includes Budd-Chiari syndrome (thrombosis of the hepatic veins, often associated with hypercoagulable states, producing painful liver engorgement and rapid ascites development) and severe right-sided heart failure causing congestive hepatopathy with elevated central venous pressure transmitted retrograde through the hepatic veins into the sinusoids.
Symptoms
Portal hypertension itself produces no direct symptoms — the clinical picture is entirely defined by its complications, which develop when collateral vessels form, the spleen enlarges, and fluid accumulates. Splenomegaly is the earliest and most consistent physical finding, often detectable on examination and invariably visible on imaging — the enlarged spleen traps platelets and white blood cells (hypersplenism), producing thrombocytopenia and leukopenia that are reliable indirect markers of significant portal hypertension. Esophageal and gastric varices — dilated submucosal veins that form as blood bypasses the obstructed portal system through the coronary vein — are the most dangerous complication: variceal hemorrhage is sudden, massive, and carries 15–20% mortality per episode. Ascites develops when the combination of portal hypertension and reduced hepatic albumin synthesis leads to transudation of fluid across the splanchnic capillary bed into the peritoneal cavity. Hepatic encephalopathy results when ammonia and other gut-derived toxins bypass hepatic detoxification through portosystemic collaterals and reach the brain. Caput medusae — a radiating pattern of dilated periumbilical veins — and hemorrhoids from dilated rectal veins are additional physical manifestations of portal collateral formation.
Diagnosis
The diagnosis is primarily clinical and imaging-based. A low platelet count, enlarged spleen on examination, and a history of chronic liver disease together constitute a highly specific clinical pattern. Upper endoscopy is essential for directly visualizing and grading esophageal and gastric varices and determining the need for prophylactic treatment. The hepatic venous pressure gradient (HVPG) — measured by hepatic vein catheterization — is the gold standard for quantifying portal pressure but is invasive and reserved for specific clinical scenarios.
An MRI of the abdomen with MR angiography (MRA) provides the most comprehensive noninvasive evaluation of the portal venous system available. MRI simultaneously characterizes the liver for underlying cirrhosis (nodular contour, parenchymal heterogeneity, caudate hypertrophy), quantifies spleen size and splenomegaly, identifies and maps collateral vessels (coronary vein, paraesophageal varices, splenorenal shunts, paraumbilical vein recanalization, retroperitoneal collaterals), and evaluates portal vein patency — detecting thrombosis, tumor thrombus from hepatocellular carcinoma, or cavernous transformation. MRI also screens for HCC in the cirrhotic liver using the LI-RADS framework, as patients with portal hypertension from cirrhosis are simultaneously at high HCC risk. This comprehensive one-stop assessment makes MRI the preferred preoperative imaging study for TIPS planning and liver transplant evaluation.
Classification
Portal hypertension is classified by the anatomic location of the obstruction, which determines the underlying etiology and guides treatment.
- Pre-hepatic: Obstruction of the portal vein or its major tributaries before the liver. Most commonly portal vein thrombosis. Liver function typically preserved. Varices and splenomegaly are present but ascites is less common. Anticoagulation is the primary treatment.
- Intrahepatic (sinusoidal): The dominant category — obstruction within the hepatic sinusoids from cirrhotic fibrosis. Both variceal hemorrhage and ascites are common. Treatment targets underlying liver disease, variceal prophylaxis, and complication management.
- Post-hepatic: Obstruction of hepatic venous outflow from Budd-Chiari syndrome or congestive heart failure. Liver is congested and often enlarged (rather than shrunken as in cirrhosis). Anticoagulation and treatment of the underlying cause are priorities; TIPS may be required for Budd-Chiari.
Treatments
Treatment targets both the underlying cause of portal hypertension and its specific life-threatening complications.
Medical management: Non-selective beta-blockers — propranolol or carvedilol (which has dual portal pressure-lowering and alpha-blocking vasodilatory effects) — reduce portal pressure by decreasing cardiac output and splanchnic vasoconstriction, lowering variceal hemorrhage risk by approximately 50%. They are the cornerstone of primary prophylaxis for medium-to-large varices. Diuretics (spironolactone and furosemide) and dietary sodium restriction manage ascites. Lactulose and rifaximin reduce encephalopathy episodes. Prophylactic antibiotics (norfloxacin or ciprofloxacin) prevent spontaneous bacterial peritonitis in high-risk patients.
Endoscopic treatment of varices.
Endoscopic variceal band ligation (EVL) — placing elastic bands around esophageal varices to obliterate them — is the primary endoscopic prophylactic and acute treatment for esophageal variceal bleeding, combined with vasoactive medications (terlipressin, octreotide) during acute hemorrhage. Gastric varices are more challenging and may be treated with cyanoacrylate tissue adhesive injection. Repeat endoscopy after each treatment session until varices are obliterated is standard practice.
TIPS (transjugular intrahepatic portosystemic shunt).
TIPS is a highly effective minimally invasive procedure in which an interventional radiologist creates a stent-lined channel connecting the portal vein to the hepatic vein through the liver parenchyma, bypassing the high-resistance intrahepatic circulation. This dramatically reduces portal pressure and effectively treats refractory ascites, recurrent variceal hemorrhage uncontrolled by endoscopy, and hepatic hydrothorax. Preoperative MRI is essential for mapping portal and hepatic venous anatomy before TIPS placement. The main risk of TIPS is worsening of hepatic encephalopathy, as portal blood bypasses hepatic detoxification — careful patient selection is required.
Liver transplantation.
For patients with cirrhosis-related portal hypertension who meet transplant criteria, liver transplantation addresses both the underlying liver disease and the portal hypertension simultaneously, with excellent long-term outcomes.
Treatment of portal vein thrombosis.
Acute portal vein thrombosis is treated with anticoagulation (low molecular weight heparin followed by warfarin or direct oral anticoagulants) when there is no contraindication from bleeding risk — the goal is recanalization and prevention of extension into the superior mesenteric vein, which can cause intestinal ischemia. Chronic cavernous transformation of the portal vein, where organized thrombus has been replaced by a network of collateral vessels, requires individualized management focused on variceal prophylaxis.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.